Zimmer Biomet Holdings, Inc. (ZBH) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 18/100
- 10Y CAGR
- 3.2%
- Median YoY
- 3%
- YoY volatility
- σ 10.7pp· uneven
- Quarters ≥ 20%
- 1 of 40
- Negative quarters
- 12
- Valuation vs own 10Y history
- Latest historical P/S 2.0x · 10Y median 3.1x · 4th percentile · as of Oct 2, 2026
How this score is computed
- Quarters at or above 20%: 1 of 40 → 1 of 40 pts
- Steadiness (typical swing 10.7pp) → 17.4 of 25 pts
- Pace (median 3% YoY) → 0 of 20 pts
- Latest quarter (4.8% YoY) → 0 of 15 pts
- Score: 18 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 3.2% | 3% | 10.7pp | 1 of 40 | 12 |
| EPSEPS | -1.5% | -11% | 58.7pp | 10 of 40 | 17 |
| Op cash flowOperating cash flow | 7% | 2.4% | 40.0pp | 8 of 40 | 17 |
| EBITDAEBITDA | 7.6% | 1.9% | 39.3pp | 5 of 40 | 17 |
| FCFFree cash flow | 7.8% | 1.3% | 53.4pp | 13 of 37 | 18 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: ZBH on the compounders surface · All compounders, ranked